Business News: AbbVie to Acquire Nimble Therapeutics and Its Oral Peptide IL23R Inhibitor
AbbVie will pay $200 million for Therapeutics, including its lead asset, an investigational oral peptide interleukin (IL)23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble’s peptide synthesis, screening, and optimization platform, which uses proprietary […]